These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 9326643)

  • 41. Mutational analysis of the SH2-kinase linker region of Bruton's tyrosine kinase defines alternative modes of regulation for cytoplasmic tyrosine kinase families.
    Guo S; Wahl MI; Witte ON
    Int Immunol; 2006 Jan; 18(1):79-87. PubMed ID: 16291652
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation.
    Fujimoto M; Poe JC; Jansen PJ; Sato S; Tedder TF
    J Immunol; 1999 Jun; 162(12):7088-94. PubMed ID: 10358152
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of the SH2 domain binding protein of Bruton's tyrosine kinase as BLNK--functional significance of Btk-SH2 domain in B-cell antigen receptor-coupled calcium signaling.
    Hashimoto S; Iwamatsu A; Ishiai M; Okawa K; Yamadori T; Matsushita M; Baba Y; Kishimoto T; Kurosaki T; Tsukada S
    Blood; 1999 Oct; 94(7):2357-64. PubMed ID: 10498607
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Paired immunoglobulin-like receptor B (PIR-B) inhibits BCR-induced activation of Syk and Btk by SHP-1.
    Maeda A; Scharenberg AM; Tsukada S; Bolen JB; Kinet JP; Kurosaki T
    Oncogene; 1999 Apr; 18(14):2291-7. PubMed ID: 10327049
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SH3 domain of Bruton's tyrosine kinase can bind to proline-rich peptides of TH domain of the kinase and p120cbl.
    Patel HV; Tzeng SR; Liao CY; Chen SH; Cheng JW
    Proteins; 1997 Dec; 29(4):545-52. PubMed ID: 9408950
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement.
    Petro JB; Rahman SM; Ballard DW; Khan WN
    J Exp Med; 2000 May; 191(10):1745-54. PubMed ID: 10811867
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The SH3 domain of Bruton's tyrosine kinase interacts with Vav, Sam68 and EWS.
    Guinamard R; Fougereau M; Seckinger P
    Scand J Immunol; 1997 Jun; 45(6):587-95. PubMed ID: 9201297
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase.
    Khan WN
    Immunol Res; 2001; 23(2-3):147-56. PubMed ID: 11444380
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of the binding site for Gqalpha on its effector Bruton's tyrosine kinase.
    Ma YC; Huang XY
    Proc Natl Acad Sci U S A; 1998 Oct; 95(21):12197-201. PubMed ID: 9770463
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling.
    Bender AT; Gardberg A; Pereira A; Johnson T; Wu Y; Grenningloh R; Head J; Morandi F; Haselmayer P; Liu-Bujalski L
    Mol Pharmacol; 2017 Mar; 91(3):208-219. PubMed ID: 28062735
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phosphorylation of Bruton's tyrosine kinase by c-Abl.
    Bäckesjö CM; Vargas L; Superti-Furga G; Smith CI
    Biochem Biophys Res Commun; 2002 Dec; 299(3):510-5. PubMed ID: 12445832
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bruton's tyrosine kinase mediates NF-kappa B activation and B cell survival by B cell-activating factor receptor of the TNF-R family.
    Shinners NP; Carlesso G; Castro I; Hoek KL; Corn RA; Woodland RT; Scott ML; Wang D; Khan WN
    J Immunol; 2007 Sep; 179(6):3872-80. PubMed ID: 17785824
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The SH3 domain of Bruton's tyrosine kinase displays altered ligand binding properties when auto-phosphorylated in vitro.
    Morrogh LM; Hinshelwood S; Costello P; Cory GO; Kinnon C
    Eur J Immunol; 1999 Jul; 29(7):2269-79. PubMed ID: 10427990
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Constitutive membrane association potentiates activation of Bruton tyrosine kinase.
    Li T; Rawlings DJ; Park H; Kato RM; Witte ON; Satterthwaite AB
    Oncogene; 1997 Sep; 15(12):1375-83. PubMed ID: 9333013
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression and activation of the nonreceptor tyrosine kinase Tec in human B cells.
    Kitanaka A; Mano H; Conley ME; Campana D
    Blood; 1998 Feb; 91(3):940-8. PubMed ID: 9446655
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tyrosine phosphorylation and activation of Bruton tyrosine kinase upon Fc epsilon RI cross-linking.
    Kawakami Y; Yao L; Miura T; Tsukada S; Witte ON; Kawakami T
    Mol Cell Biol; 1994 Aug; 14(8):5108-13. PubMed ID: 7518558
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Syk, but not Lyn, recruitment to B cell antigen receptor and activation following stimulation of CD45- B cells.
    Pao LI; Cambier JC
    J Immunol; 1997 Mar; 158(6):2663-9. PubMed ID: 9058799
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bruton's tyrosine kinase is required for signaling the CD79b-mediated pro-B to pre-B cell transition.
    Kouro T; Nagata K; Takaki S; Nisitani S; Hirano M; Wahl MI; Witte ON; Karasuyama H; Takatsu K
    Int Immunol; 2001 Apr; 13(4):485-93. PubMed ID: 11282988
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tyrosine phosphorylation of the Wiskott-Aldrich syndrome protein by Lyn and Btk is regulated by CDC42.
    Guinamard R; Aspenström P; Fougereau M; Chavrier P; Guillemot JC
    FEBS Lett; 1998 Sep; 434(3):431-6. PubMed ID: 9742969
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reduced dosage of Bruton's tyrosine kinase uncouples B cell hyperresponsiveness from autoimmunity in lyn-/- mice.
    Whyburn LR; Halcomb KE; Contreras CM; Lowell CA; Witte ON; Satterthwaite AB
    J Immunol; 2003 Aug; 171(4):1850-8. PubMed ID: 12902486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.